Mobile

A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (ant...

Update Il y a 5 ans
Reference: EUCTR2008-008359-40

A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Efficacy of AIN457 at 6 weeks on mean CDAI

Inclusion criteria

  • Moderate to severe Crohn's disease (CDAI = 220 and =450)

Links